$GALT Becoming more bullish. I realize mistakes have been made by management in the past. Wrong dose, wrong trial duration.. However, this adaptive design trial has a double trial built into it, that is; assessment of Hepatic Impairment The FDA is realizing that just reducing fibrosis by a level does not correlate with liver function— making proteins, detoxifying compounds for excretion This adaptive trial becomes even more powerful because it can prove our worth two ways- prevention of varices and prevention of liver deterioration And we get interim data in one year Good stuff
  • 11
  • 14